Mark A. Titus, Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | University of Washington, Seattle, WA, USA, PHD, Medicinal Chemistry |
| 1987 | University of Washington, Seattle, WA, USA, Post Bacc, Physical Chemistry |
| 1983 | University of Oregon, Eugene, OR, USA, BS, Biology |
Experience & Service
Academic Appointments
Assistant Professor, Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, 2007 - 2012
Research Associate, Division of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 2005 - 2007
Postdoctoral Fellow, Department of Surgery, Division of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, 2001 - 2005
Mellon Postdoctoral Fellow, Department of Pediatrics - Research, University of North Carolina School of Medicine, Chapel Hill, NC, 1998 - 2001
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol 21(1):86-94, 2019. e-Pub 2018. PMID: 29748904.
- Adelaiye-Ogala R, Damayanti NP, Orillion AR, Arisa S, Chintala S, Titus MA, Kao C, Pili R. Therapeutic targeting of sunitinib-induced AR phosphorylation in renal cell carcinoma. Cancer Res 78(11):2886-2896, 2018. e-Pub 2018. PMID: 29572225.
- Yu G, Cheng CJ, Lin SC, Lee YC, Frigo DE, Yu-Lee LY, Gallick GE, Titus MA, Nutt LK, Lin SH. Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II. Cancer Res 78(10):2490-2502, 2018. e-Pub 2018. PMID: 29535221.
- Zhang B, Kwon OJ, Henry G, Malewska A, Wei X, Zhang L, Brinkley W, Zhang Y, Castro PD, Titus M, Chen R, Sayeeduddin M, Raj GV, Mauck R, Roehrborn C, Creighton CJ, Strand DW, Ittmann MM, Xin L. Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. Mol Cell, 2016. e-Pub 2016. PMID: 27594448.
- Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Oncotarget. Caveolin-1 Regulates Hormone Resistance Through Lipid Synthesis, Creating Novel Therapeutic Opportunities For Castration-Resistant Prostate Cancer. Oncotarget, 2016. PMID: 27331874.
- Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30(6):637-43, 2012. e-Pub 2011. PMID: 22184395.
- Titus MA, Zeithaml B, Kantor B, Li X, Haack K, Moore DT, Wilson EM, Mohler JL, Kafri T. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One 7(1):e30192, 2012. e-Pub 2012. PMID: 22272301.
- Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 17(18):5844-9, 2011. e-Pub 2011. PMID: 21705451.
- Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, Titus MA, Mohler JL. 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 71(10):1033-46, 2011. e-Pub 2010. PMID: 21557268.
- Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71(14):1486-96, 2011. e-Pub 2011. PMID: 21303972.
- Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res. e-Pub 2020. PMID: 31941830.
Other Articles
- Mark A Titus, Daniel Frigo, Eleni Efstathiou, Christopher J Logothetis, David Piwnica-Worms, Pratip Bhattacharya Metabolic Imaging in Prostate Cancer- Beyond the Abstract. UroToday, 2018.
Abstracts
- Efstathiou E, Li W, Gormley M, McMullin R, Ricci D, Davis JW, Tapia E, Troncoso P, Titus M, Anh Hoang, Sijin Wen, Amado J. Zurita, Tran N-P, Peng W, Kheoh T, Molina A, Logothetis CJ. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. J Clin Oncol, 2015.
- McCullough C, Zacharias N, Kaluarachchi K, Titus M, Bhattacharya P. Metabolic profiling and investigation of cellular models and tissue samples of advanced prostate cancer. ISMRM, 2015.
- Efstathiou E, Troncoso P, Ning Tapia EL, Davis JW, Titus MA, Hoang A, Prokhorova IN, Wen S , Logothetis C. Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC). J Clin Oncol, 2015.
- Maity SN, Titus M, Wu G, Lu JF, Ramachandran S, Eisner JR, Hoekstra WJ, Schotzinger RJ, Moore WR, Logothetis CJ, Araujo JC, Efstathiou E. Effect of a selective CYP17-lyase inhibitor, VT-464, on androgen receptor signaling in prostate cancer cells and on tumor growth of a patient-derived castrate-resistant prostate cancer xenograft. AACR-PCF Annual Meeting, 2014.
- Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu S-M, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol, 2014.
- Ramachandran S, Mitri Z, Maity S, Araujo J, Efstathiou E, Logothetis CJ, Titus M. Steroid profiles in metastatic bone prostate cancer models using LC/MSMS. ASMS Annual Conference, 2014.
- Titus M, Araujo J, Yang J, Ramachandran S, Efstathiou E, Troncoso P, Logothetis C, Navone N.. Intra-tumor metabolite profile of a treatment naïve patient-derived bone metastatic prostate cancer xenograft. 21st Annual PCF Scientific Retreat, 2014.
- Maity S, Titus M, Wu G, Lu J-F, Ramachandran S, Eisner JR, Rafferty SW, Schotzinger RJ, Moore WR, Logothetis CJ, Araujo JC, Efstathiou E.. A novel selective inhibitor of cytochrome P450 17,20 lyase, in castrate-persistant prostate cancer. AACR Annual Meeting, 2013.
- Efstathiou E, Titus M, Wen S, San Miguel A, Hoang A, deHaas-Amatsaleh A, Perabo FGE, Phung D, Troncoso P, Logothetis CJ. The effects of Enzalutamide (ENZA) in combination with Abiraterone Acetate (AA) in patients with bone metastatic Castration Resistant Prostate Cancer (mCRPC). 20th Annual PCF Scientific Retreat, 2013.
- Moore WR, Maity SN, Eisner JR, Garvey EP, Hoekstra WJ, Titus M, Logothetis CJ, Araujo JC, Efstathiou E, Schotzinger RJ. The enzymology of the selective CYP17 lyase nnhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. GU-ASCO Annual Meeting, 2013.
- Moore WR, Toren P, Eisner JR, Garvey EP, Hoekstra WJ, Titus M, Logothetis CJ, Araujo JC, Efstathiou E, Gleave M, and Schotzinger RJ. The effects of VT-464, a selective inhibitor of cytochrome P450 17, 20-lyase, in castration-resistant prostate cancer (CRPC) models. 20th Annual PCF Scientific Retreat, 2013.
- Efstathiou E, Titus M, Tsavachidou D, Wen S, Hoang A, Ashe R, Karlou M, Berman C, Troncoso P, Mohler J, Logothetis CJ. Modulation of intracrine androgen signaling in bone metastatic castrate resistant Prostate cancer (bmCRPC) by MDV3100. AACR Annual Meeting, 2012.
- Efstathiou E, Davis JW, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Molina A, Logothetis C.. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. J Clin Oncol, 2012.
Book Chapters
- Lin C, Salzillo TC, Bader DA, Wilkenfeld SR, Awad D, Pulliam TL, Dutta P, Pudakalakatti S, Titus M, McGuire SE, Bhattacharya PK, and Frigo DE. Prostate Cancer Energetics and Biosynthesis. In: Prostate Cancer Advances in Experimental Medicine and Biology. Springer Nature: Switzerland, 2019.
- Titus M, Tomer KB. Androgen quantitation in prostate cancer tissue using liquid chromatography tandem mass spectrometry. In: Methods Mol Biol. Humana Press: New York, NY, 47-58, 2011.
- Mohler JL, Titus MA, Godoy AS, Oka D, Nelson PS. Intracrine synthesis of androgens by prostate cancer in response to androgen deprivation therapy. In: Recent Advances in Prostate Cancer. World Scientific Publishing Co. Pte. Ltd: Singapoare, 193-218, 2011.
- Titus MA, Mohler JL. 5α-Reductase isozymes in castration-recurrent prostate cancer. In: Androgen Action in Prostate Cancer. Springer: New York, NY, 175-186, 2009.
- Mohler JL, Titus MA. Tissue levels of androgens in castration-recurrent prostate cancer. In: Androgen Action in Prostate Cancer. Springer: New York, NY, 553-568, 2009.
Grant & Contract Support
| Title: | Steroid 5α-Reductase-3 Promotes the Progress of Prostate Cancer to Recurrent Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | Prostate Cancer: Transition to Androgen Independence, Project 1: Interference with the Androgen Receptor and its Ligands in Recurrent Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Mechanism of Resistance to Androgen Biosynthesis Inhibition in Castrate-Resistant Prostate Cancer Bone Metastases |
| Funding Source: | Prostate Cancer Foundation |
| Role: | Co-Investigator |
| Title: | Differentiation Signaling in Prostate Stem Cells |
| Funding Source: | NIH/NIDDK |
| Role: | Collaborator |
| Title: | Steroid Metabolome in the Progression of Prostate Cancer to Resistant Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Metabolic Profiling of Core Biopsies from Finasteride Exposed and Unexposed Early Stage Prostate Cancer: Toward Risk Stratification by In Vivo Metabolic Imaging |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-Investigator |
| Title: | Imaging Local Prostate Heterogeneity by Monitoring Citrate Acid Cycle Metabolites and Cholesterol Precursor Metabolites |
| Funding Source: | MD Anderson Moon Shot Program |
| Role: | Principal Investigator |
| Title: | Conduct Opportunistic Anti-Androgen Combination Therapy Trails and Develop Methods for Comprehensive Analysis of Response |
| Funding Source: | MD Anderson Moon Shot Program |
| Role: | Investigator |
| Title: | Optimizing Androgen Signaling Inhibition to Transition from a Treatment to a Curative Paradigm |
| Funding Source: | MD Anderson Moon Shot Program |
| Role: | Co-Investigator |
| Title: | Identifying Metabolic Events Driving Prostate Cancer Progression to Anti-androgen Resistance |
| Funding Source: | Emerson Collective Research Fund |
| Role: | Co-Investigator |
| Title: | Contribution of Cancer Cell Intrinsic and Extrinsic Androgen Receptor Signaling to Prostate Cancer and Influence of the Western Diet |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | Flagship 1: Development of Mechanism-based Combination Therapies for Castration-Resistant Prostate Cancer |
| Funding Source: | MD Anderson Moon Shot Program |
| Role: | Investigator |
| Title: | A novel therapy targeting prostate cancer-induced aberrant bone formation |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |